Clearmind Medicine Inc. (NASDAQ: CMND), an Israel-based biotech company advancing the clinical stage for an MEAI-based compound targeting Alcohol Use Disorder (AUD,) has selected Yale School of Medicine’s Psychiatry Dept. as the first U.S. site for its Phase 1/2a trial on proprietary CMND-100.

CEO Dr. Adi Zuloff-Shani says the company is honored to partner with the university’s Psychiatry Department, “a global pioneer in psychedelics research,” and sees the collaboration as “further validation” of its innovative drug candidate for the potential treatment of AUD.

Within the newly-announced U.S. site, the study will be led by substance abuse specialist and Yale psychiatry professor Dr. Anahita Bassir Nia, whom Dr. Zuloff-Shani says is ideal for the task considering “her research focuses on addiction and mental health disorders, and she is particularly interested in the biological effects of acute and chronic stress on-developing substance use disorders.”

The Phase 1/2 single …

Full story available on

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.